Dasiprotimut-T

Drug Profile

Dasiprotimut-T

Alternative Names: Autologous immunoglobulin follicular lymphoma idiotype vaccine - Biovest/NCI; B-cell lymphoma vaccine - Biovest; BiovaxID; FNHLId1; Lympreva

Latest Information Update: 12 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Biovest International; National Cancer Institute (USA)
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Follicular lymphoma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Follicular lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 12 Jul 2017 Discontinued - Phase-II for Mantle cell lymphoma in USA (SC)
  • 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in Russia and Ukraine (SC)
  • 12 Jul 2017 Discontinued - Phase-III for Follicular lymphoma (Late-stage disease) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top